Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $146.23 -3.69%
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +30.8%
Financial Fact:
Total operating expenses: 38.44M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.81, $0.29 better than the analyst estimate of $1.52. Revenue for the quarter came in at $622.1 million versus the consensus estimate of $600.97 million.
GUIDANCE:
Neurocrine Biosciences sees FY2024 revenue of $2.3-2.32 billion, versus the consensus of $2.33 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform
- RBC Capital Reiterates Sector Perform Rating on Freehold Royalties Ltd. (FRU:CN) (FRHLF)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
